Introduction
Since the definition by Isaacson and Wright in the early 1980s [1] of lymphoma of mucosa-associated lymphoid tissue (MALT) as a distinct entity, clinico-pathologic, MALT-type lymphoma has been a focus of interest for both pathologists and clinicians. This non-Hodgkin's lymphoma of B cell origin is rated as an extranodal marginal zone lymphoma of MALT-type in the R.E.A.L. Classification [2] . The MALT lymphoma concept suggests that these tumors, which can be of low-and/ or high-grade histology, arise against the background of chronic antigenic stimulation, triggered by persistent infections, as exemplified by Helicobacter pylori (H. pylori) or certain autoimmune processes [3] . Transformation of low-grade MALT lymphoma in the course of the disease is a frequently observed phenomenon resulting in a more aggressive behaviour of the otherwise relatively indolent neoplasm [4] . Consequently, high-grade MALT-type lymphoma is not responsive to eradication of H. pylori, while most patients with localized low-grade lesions show complete remission of the lymphoma after antibiotic therapy [4] . While the majority of extranodal B-cell lymphomas of MALT-type occur in the stomach, they can arise in virtually every organ of the human body including salivary glands, and thyroid, lung, skin, and ocular adnexa [5, 6] , with disseminated occurrence in about 1/3 of cases [7] .
Eradication of H. pylori has repeatedly been demonstrated to result in complete regression of gastric lymphoma in patients with localized low-grade disease, and the use of radiation has yielded promising results in patients with localized lymphoma of both gastric and extragastric origin. These approaches, however, are not currently believed to be useful in patients with disseminated disease [8] . Thus, determining the extent of disease in patients with MALT-type lymphoma is of critical importance for treatment planning. However, the occurrence of acquired MALT in a large number of organs and the pronounced homing tendency of MALT-type lymphoma requires extensive staging in these patients to rule out multifocal occurrence or distant spread once a histologic diagnosis has been established. Staging procedures should target the most common organs known to harbor MALT and thus include opthalmologic and otolaryngologic evaluation, gastroscopy with multpiple biopsies, endosonography, enteroclysis, colonoscopy, CT scanning of thorax and abdomen and bone marrow biopsy. Due to the necessity for extensive staging in such patients, methods providing additional information with the potential for shortening both pretherapeutic workup as well as follow-up are still warranted.
Fluorine-18-2-fluoro-2-deoxy-D-glucose (F18-FDG) is the most widely applied positron emission tomography (PET) tracer used to survey cell metabolism. The metabolic turnover of tumor cells usually exceeds physiologic metabolic activity, and excessive FDG uptake has consequently been demonstrated in most malignant tumors in vivo, rendering FDG-WB-PET an excellent staging method in various malignancies including malignant lymphomas of indolent or aggressive behavior [9] [10] [11] [12] [13] . While initially applied as a research instrument, the use of this imaging technique for tumor staging has become a clinical reality with the advent'of PET cameras capable of producing whole-body scans (WB-PET) in an hour or less with high imaging quality and linear spatial resolutions well below one centimeter [14] .
Based on the fact that not only aggressive lymphomas with an accelerated growth, but also indolent lymphomas, have successfully been imaged with FDG-WB-PET [15] , we initiated a prospective study to evaluate the clinical usefulness of this method for the staging and follow-up of patients with extranodal B-cell lymphoma of MALT-type.
Patients and methods
A total of 10 consecutive patients (6 female, 4 male) with histologicallyverified extranodal B-cell lymphoma of MALT type were included in our pilot series. All patients underwent scanning with FDG-WB-PET before initiation of treatment, and scanning results were compared to conventional staging that had been completed not more than three weeks previously. Standardized staging procedures applied in all patients included ophthalmologic investigation, otolaryngologic examination, gastroscopy with multiple biopsies, endosonography, enteroclysis, colonoscopy, CT of thorax and abdomen and bone marrow biopsy. In all lesions suggestive of lymphoma involvement both on conventional imaging as well as on FDG-WB-PET, a biopsy was performed, and biopsy specimens were evaluated by a reference hemato-pathologist. In instances of lesions not accessible to biopsy or not documented on conventional imaging, follow-up was performed at a maximum interval of 8-12 weeks.
Histologic diagnosis of lymphoma of MALT type was established according to the criteria outlined by Isaacson [1] . In addition, immunologic phenotyping on paraffin sections was carried out to demonstrate light chain restriction indicating monoclonal B-cell proliferation and all samples were evaluated for the phenotype CD2O+CD5-CD10-which, in conjunction with the microscopic appearance, is consistent with low-grade B-cell lymphoma of MALT type [3] . The diagnosis of high-grade MALT-type lymphoma was based on the presence of sheets of large cells with blastic appearance together with a low grade component, and was also confirmed by phenotyping.
Nine patients had low-grade lymphoma of MALT type (five gastric lymphomas, two lung, one parotid and one lacrimal gland lymphoma), while one patient had a high-grade gastric lymphoma with a low-grade component. The patient profile is summarized in Table 1 .
Staging was performed according to the Ann Arbor classification as modified by Musshoff [16] : in stage El the lymphoma is confined to the wall of the stomach or intestine, in stage EII, there is involvement of regional lymph nodes contiguous with the primary site, whereas in stage EII 2 there is involvement of a regional, but non-contiguous lymph node group. Stage EIII refers to involvement on both sides of the diaphragm, and stage IV signifies dissemination to the bone marrow or other non-lymphoid organs. Staging revealed the presence of stage El disease in two patients, while seven had stage EII (EII, in five and EI1 2 in two cases), and one patient had stage EIII, with the median size of lesions being 2.5 cm (range 1-5.5 cm).
FDG-WB-PET scans were performed on a GE Advance PET scanner (GE Medical Systems, Waukesha, WI) with a whole body mode implemented as standard software. PET emission scanning was started 40 min following the injection of 300-380 MBq of F18-FDG and performed from the head to the pelvic floor. To improve image quality patients had to fast for at least four hours prior to FDG-PET. The acquired data were reconstructed using standard back-projection techniques in axial sections and were reformatted into coronal and sagittal views. Additional transmission scanning for attenuation correction was performed in areas showing suspicious lesions in the emission scan. In only one patient was whole body transmission scanning with subsequent iterative reconstruction carried out (Figures la, b) . Scan results were evaluated in a single-blinded way, i.e., without prior knowledge of tumor spread, and compared to conventional staging as outlined above.
Results
All 10 patients underwent scanning as scheduled. The results, however, were disappointing in that FDG-WB-PET scanning did not visualize histologically verified lesions in any of the ten patients studied. In three patients the scan showed a false negative result concerning the documented MALT lesion but indicated a lesion mimicking tumor spread: in one patient with a lowgrade gastric MALT-type lymphoma, FDG-WB-PET revealed an intense hot spot in the right paravertebral area as well as diffuse high FDG uptake projected to the duodenum and the small intestine. A histological work-up of multiple duodenal biopsies obtained during endoscopy performed one week after the FDG-WB-PET provided no evidence of lymphoma or any other pathological changes, suggesting unspecific tracer accumulation. Abdominal CT scans performed one week after FDG-WB-PET and again after a wait-and-see period of eight weeks showed no lesions suggestive of lymphomatous involvement in the corresponding areas. In a second patient presenting with low-grade lymphoma of the stomach (endosonography, Figure 2 ) focal tracer-uptake in the mediastinum was documented (Figures la, b) , while the primary lymphoma as well as local lymph nodes were not visualized. Spiral-CT scan performed two weeks later did not indicate the presence of enlarged lymph nodes or intrapulmonary lesions. Yet, a CT scan done six months after the PET scan revealed an encapsulated lesion in the anterior mediastinum corresponding to our former finding in the PET scan. Endosonographic biopsy of this lesion with consecutive histological evaluation demonstrated an abscess without evidence of lymphoma.
In one patient with pulmonary MALT-type lymphoma, FDG-WB-PET did not visualize the documented lesion in the left upper lobe, but showed diffuse tracer-uptake covering the upper left hemithorax. While bronchoscopy confirmed the presence of low-grade MALT-type lymphoma in the lesion seen on CT, only slight unspecific inflammation, but no evidence of diffuse lymphoma involvement could be documented by multiple biopsies. In this case, the elevated pulmonary uptake was rated as unspecific inflammation. In view of the disappointing results obtained in the first 10 patients, the study was discontinued.
Discussion
Positron emission tomography using FDG-WB-PET has been demonstrated to be a useful imaging tool in a wide variety of human cancers such as malignant melanoma, lung, colorectal, breast, cervical and head-andneck cancer [9, 14, 17] . In addition, lymphomas of both aggressive and indolent subtypes have been reported to be avid for FDG [10, 12, 13, 15] . Thus, our objective was to determine the usefulness of FDG-WB-PET for staging and potential follow-up of patients with extranodal B-cell lymphomas of the MALT type. Due to the highly disappointing results in all 10 patients, however, recruitment was stopped after our first interim analysis, since FDG-WB-PET was not able to visualize any documented neoplastic lesion in patients with either gastric or extragastric lymphoma. In addition to these negative results in terms of correct correlation with conventional staging and histological examination, a relatively high rate of false positive scans was found. These results differ from results obtained in solid tumors as published in the current literature [14, 17] . High specificities of FDG-PET results were reviewed by Hoh et al. including head and neck cancer, malignant melanoma, recurrent breast cancer, and mediastinal staging in lung cancer [14] . Flamen et al. analyzed 103 patients with recurrent colorectal cancer and found only four false positve results [17] . In addition, Stumpe et al. found no false positive results in 53 patients with Hodgkin's disease and 18 patients with non-Hodgkin's lymphoma [12] . On the other hand, a review of the literature concerning false negative results in indolent lymphoma revealed only two single cases (Rodriguez, Goldberg) .
One explanation for negative results obtained in the imaging of gastric MALT-type lymphomas might be the fact that such lesions often present as strictly localized processes involving only mucosa and submucosa [20] , and thus might not be reached by the tracer or might simply be too small to be detected by current techniques applied due to the limit of resolution. Nevertheless, this explanation seems highly unlikely in our series, since it would hold true for only one of the patients included in our study (patient no. 2, see Table 1 ) presenting with disease restricted to the gastric mucosa and submucosa. All other patients with gastric lymphoma investigated had additional lymph node involvement, and the second patient with stage El had a lymphoma of the lung measuring 3.5 cm in diameter.
However, it might be argued that the biology of MALT-type lymphoma, which usually displays a very indolent course [5] , would per se implicate a low glucose metabolism in these lymphomas, rendering imaging of such lesions with FDG-WB-PET a futile attempt. While extranodal B-cell MALT-type lymphoma is apparently characterized by absence of FDG uptake as measured by FDG-WB-PET, various studies have reported successful imaging of indolent nodal lymphomas with a relatively low proliferative activity [10, 21, 22] , as has also been demonstrated at our institution (own, unpublished data). In addition, one patient with a high-grade gastric lymphoma arising within a low-grade background also had a negative scan despite a relatively large primary lesion in the stomach along with local lymph node involvement (patient no. 3, see Table 1 ).
The successful clinical use of FDG-WB-PET in various tumors has been related to the relative deficiency of glucose-6-phosphatase, upregulation of hexokinase activity as well as changes in the levels of glucose membrane transporters. In addition, alterations in the expression of glucose transporter genes in tumor cells may have an impact on FDG uptake [23, 24] . According to this concept, FDG-WB-PET functions as an in vivo indicator of functional glycolysis and allows visualization of tumors with a high glucose uptake. In this regard our data suggest a clinical difference between solid tumors and MALT-type lymphomas, but also between nodal lymphomas and extranodal B-cell lymphomas of MALT-type. No extensive in vitro examinations have been performed concerning the expression of enzymes related to glucose utilization in MALT-type lymphomas, but the results obtained in this study warrant further investigation of the metabolic properties of extranodal MALT-type lymphomas as compared to nodal lymphomas.
From the clinical perspective, however, not only does the inability of FDG-WB-PET to visualize any lymphomatous lesion deserve consideration, but also the fact that a relatively high rate of false positive results was obtained in our series. As with most malignant processes, patient management is highly dependent on the accurate evaluation of the tumor burden. In contrast to any other malignancy, however, localized gastric MALT-type lymphoma is (currently) the only example of an antigen-dependent type of tumor with the potential for total regression following elimination of the antigen [8] . A conservative approach with regular followup seems nevertheless only applicable in patients with lymphoma restricted to the mucosa and submucosa [8] . Therefore, a false positive scan would result in a different approach with potential over-treatment. On the other hand, patients thought to have disseminated disease would usually not be considered candidates for potentially curative therapy such as local irradiation in patients with both gastric and extragastric MALT-type lymphoma.
Despite the fact that FDG-WB-PET has become a routine procedure for staging many malignancies, our results clearly indicate that FDG-WB-PET is not useful in the staging, and thus also in the follow-up of patients with MALT-type lymphoma. Although our series includes only ten patients, we did not feel it justified to investigate a larger cohort of patients because of the consistently negative results at histologically-verified sites of MALT-type lymphoma. The only sites of glucose utilization we could visualize tended to be areas of unspecific FDG uptake. According to these disappointing results, further use of FDG-WB-PET in patients with MALT-type lymphoma cannot be recommended, since inclusion of FDG-WB-PET in the decision making process would put patients at risk for unsuitable therapeutic approaches. Further investigations with other PET tracers, e.g., HC-Methionine, HC-Tyrosine or 18F-alphamethyl-tyrosine are warranted in order to demonstrate their impact on the diagnostic trail in MALT-type lymphoma.
